ArticleActa biomaterialia2026
Revisiting the tension-free paradigm: Axially prestretched elastomeric nanofibrillar grafts restore artery-like axial biomechanics in a preclinical model.
Article in Acta biomaterialia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Healthy arteries function under substantial axial prestretch (AP), the ratio of in vivo to unloaded ex vivo length. Loss of AP promotes tortuosity and disturbed hemodynamics associated with vascular pathology, yet artery-like AP has not been incorporated in vascular reconstructions, because conventional substitutes are axially stiff and cannot safely sustain physiological AP. Here, we present Axially Prestretched Elastomeric Nanofibrillar Grafts (APENGs), fabricated by ultrahigh-speed (43,000 rpm) rotational collector electrospinning of biomedical-grade polyurethane. APENGs matched native arterial axial stiffness and tolerated elastomeric elongation beyond AP = 1.5 without failure, excessive force generation, or plastic deformation, while maintaining adequate suture retention, permeability, and burst strength. In vitro, APENGs supported endothelial cytocompatibility and low hemolysis. In a bilateral swine carotid interposition model (8 grafts, two-week follow-up), experimental APENGs (nominal AP ≈ 1.5) achieved and retained elevated prestretch and reduced tortuosity relative to contralateral controls (nominal AP ≈ 1.0). Patency was 75% (prestretched) versus 100% (controls). Histology showed rapid mid-graft endothelialization, early smooth muscle ingrowth, and limited neointimal thickening near anastomoses. This study demonstrates the first synthetic graft implanted with controlled, artery-like AP, challenging the tension-free anastomosis paradigm and positioning AP as a vascular graft design lever to restore native artery biomechanics and mechanobiology. STATEMENT OF SIGNIFICANCE: AP is an essential homeostatic state of healthy arteries that supports arterial biomechanics and mechanobiology. Reduction in AP is associated with tortuosity, disturbed flow, and maladaptive vascular responses, yet its mechanisms remain understudied. AP is absent from current grafts, which are too stiff to safely sustain physiological elongation, forcing tension-free implantation and leaving axial biomechanics unrestored. Here, we present APENGs, manufactured by ultrahigh-speed rotational electrospinning to achieve artery-like low axial stiffness. In a swine carotid interposition model, APENGs with controlled physiological AP demonstrated surgical feasibility, reduced tortuosity, biomimetic pulsatility, and early endothelialization. These findings challenge the tension-free paradigm and establish APENGs as a platform for restoring and studying AP-regulated vascular biomechanics and remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.